Learn how to manage chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) at work, including legal protections, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...

Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a chronic autoimmune condition that affects the protective layer around your nerves, usually starts with one of three options.

For more than 15 years, Glenanne Ball has been living with a rare chronic autoimmune disease that attacks the protective ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...

Argenx SE gained U.S. FDA approval of subcutaneously given Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Standard treatment for many autoimmune diseases includes drugs that suppress the immune system. Even when this approach works (and it doesn’t work for everyone), chronic immunosuppression puts ...

Takeda is making its first foray into rare disease marketing on connected TV (CTV). The Japanese biotech recently launched a video campaign for its chronic inflammatory demyelinating polyneuropathy ...